A piece of the puzzle: What does BRAF status mean in the management of patients with papillary thyroid carcinoma?

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 9, 2012, Pages 3094-3096

  Sarne, David H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE;

BRAF GENE; CANCER STAGING; DISEASE ASSOCIATION; DISTANT METASTASIS; EDITORIAL; ENZYME ACTIVATION; HUMAN; LYMPH NODE METASTASIS; MUTATOR GENE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THYROID PAPILLARY CARCINOMA;

CARCINOMA, PAPILLARY; FEMALE; HUMANS; MALE; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84866175310     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2760     Document Type: Editorial

References (20)

1. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762 (Pubitemid 350294294)
2. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park DJ 2012 The association of the BRAFv600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118:1764-1773
3. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, Yip L, Seethala RR, Tublin ME, Stang MT, Coyne C, Johnson JT, Stewart AF, Nikiforova MN 2011 Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 96:3390-3397
4. Handkiewicz-Junak D, Czarniecka A, Jarzab B 2010 Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol 322:8-28
5. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R 2006 Correlation between B-RAFV600E mutation and clínico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13:455-464 (Pubitemid 43886668)
6. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A 2009 BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathologic features and disease-free survival of patients. Endocr J 56:89-97
7. Ricarte-Filho J, Ganly I, Rivera M, Katabi N, Fu W, Shaha A, Tuttle RM, Fagin JA, Ghossein R 2012 Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases and extra-nodal extension. Thyroid 22:575-584
8. Sancisi V, Nicoli D, Ragazzi M, Piana S, Ciarrocchi A 2012 BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab 97:E1745-E1749
9. Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G, Vitale M 2012 The primary occurrence of BRAFV600E is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 97:517-524
10. Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G 2008 BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 68:618-634 (Pubitemid 351388702)
11. Vasko V, Hu S, Wu G, Xing JC, Larin A, Savchenko V, Trink B, Xing M 2005 High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 90:5265-5269 (Pubitemid 41262284)
12. Sassolas G, Hafdi-Nejjari Z, Ferraro A, Decaussin-Petrucci M, Rousset B, Borson-Chazot F, Borbone E, Berger N, Fusco A 2012 Oncogenic alterations in papillary thyroid cancers of young people. Thyroid 22:17-26
13. Paulson L, Shindo M, Schuff K, Corless C 2012 The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 138:44-49
14. Mathur A, Moses W, Rahbari R, Khanafshar E, Duh QY, Clark O, Kebebew E 2011 Higher rate of BRAF mutation in papillary thyroid cancer over time. Cancer 117:4390-4395
15. Romei C, Fuggazzola L, Puxeddu E, Frasca F, Viola D, Muzza M, Moretti S, Nicolosi ML, Giania C, Cirello V, Avenia N, Rossi S, Vitti P, Pinchera A, Elisei R 2012 Modifications in the papillary thyroid cancer gene profile over the last 15 years. J Clin Endocrinol Metab 97:E1758-E1765
16. Cheng S, Serra S, Mercado M, Ezzat S, Asa SL 2011 A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res 17:2385-2394
17. Finkelstein A, Levy GH, Hui P, Prasad A, Virk R, Chhieng DC, Carling T, Roman SA, Sosa JA, Udelsman R, Theoharis CG, Prasad ML 2012 Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology 60:1052-1059
18. Eloy C, Santos J, Soares P, Sobrinho-Simões M 2011 The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch 459:265-276
19. Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, Park WC, Kim JS, Jung SS, Bae JS 2012 Is the BRAFV600E mutation useful as a predictor of preoperative risk in papillary thyroid carcinoma? Am J Surg 203:436-441
20. Burningham AR, Krishnan J, Davidson BJ, Ringel MD, Burman KD 2005 Papillary and follicular variant of papillary carcinoma of the thyroid: initial presentation and response to therapy. Otolaryngol Head Neck Surg 132:840-844 (Pubitemid 40798404)